Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.4
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 11791173
Nakamura T, et al. (2002) Discrimination between phosphotyrosine-mediated signaling properties of conventional and neuronal Shc adapter molecules. Oncogene 21, 22-31 11791173
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

Y218-p - SHC3 iso2 (human)
Modsite: GDGSDHPyyNSIPSK SwissProt Entrez-Gene
Orthologous residues
SHC3 (human): Y341‑p, SHC3 iso2 (human): Y218‑p, SHC3 (mouse): Y221‑p, SHC3 (rat): Y341‑p
Characterization
Methods used to characterize site in vivo [32P] bio-synthetic labeling, mutation of modification site, phospho-antibody, phosphopeptide mapping
Disease tissue studied:  adrenal cancer, pheochromocytoma
Relevant cell lines - cell types - tissues:  COS (fibroblast), PC-12 (chromaffin)
Cellular systems studied:  cell lines
Species studied:  green monkey, rat
Enzymes shown to modify site in vitro
Type Enzyme
KINASE TrkA (human)
KINASE EGFR (human)
KINASE TrkB (human)
KINASE Src (human)
KINASE TrkA (human)
KINASE Src (human)
KINASE TrkB (human)
KINASE TrkA (human)
KINASE TrkB (human)
KINASE EGFR (human)
KINASE EGFR (human)
KINASE Src (human)
Downstream Regulation
Effect of modification (function):  molecular association, regulation
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
RAPGEF1 (human) Induces pull-down assay
CRK (human) Induces pull-down assay

Y219-p - SHC3 iso2 (human)
Modsite: DGSDHPyyNSIPSKM SwissProt Entrez-Gene
Orthologous residues
SHC3 (human): Y342‑p, SHC3 iso2 (human): Y219‑p, SHC3 (mouse): Y222‑p, SHC3 (rat): Y342‑p
Characterization
Methods used to characterize site in vivo [32P] bio-synthetic labeling, mutation of modification site, phospho-antibody, phosphopeptide mapping
Disease tissue studied:  adrenal cancer, pheochromocytoma
Relevant cell lines - cell types - tissues:  COS (fibroblast), PC-12 (chromaffin)
Cellular systems studied:  cell lines
Species studied:  green monkey, rat
Enzymes shown to modify site in vitro
Type Enzyme
KINASE Src (human)
KINASE Src (human)
KINASE EGFR (human)
KINASE EGFR (human)
KINASE Src (human)
KINASE EGFR (human)
KINASE TrkA (human)
KINASE TrkA (human)
KINASE TrkB (human)
KINASE TrkB (human)
KINASE TrkA (human)
KINASE TrkB (human)
Downstream Regulation
Effect of modification (function):  molecular association, regulation
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
RAPGEF1 (human) Induces pull-down assay
CRK (human) Induces pull-down assay

Y256-p - SHC3 iso2 (human)
Modsite: FAGKEQTyyQGRHLG SwissProt Entrez-Gene
Orthologous residues
SHC3 (human): Y379‑p, SHC3 iso2 (human): Y256‑p, SHC3 (mouse): Y259‑p, SHC3 (rat): Y379‑p
Characterization
Methods used to characterize site in vivo [32P] bio-synthetic labeling, mutation of modification site, phospho-antibody, phosphopeptide mapping
Disease tissue studied:  adrenal cancer, pheochromocytoma
Relevant cell lines - cell types - tissues:  COS (fibroblast), PC-12 (chromaffin)
Cellular systems studied:  cell lines
Species studied:  green monkey, rat
Enzymes shown to modify site in vitro
Type Enzyme
KINASE TrkA (human)
KINASE Src (human)
KINASE Src (human)
KINASE EGFR (human)
KINASE EGFR (human)
KINASE TrkB (human)
KINASE TrkB (human)
KINASE TrkA (human)
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
NGF increase
EGF increase

Y257-p - SHC3 iso2 (human)
Modsite: AGKEQTyyQGRHLGD SwissProt Entrez-Gene
Orthologous residues
SHC3 (human): Y380‑p, SHC3 iso2 (human): Y257‑p, SHC3 (mouse): Y260‑p, SHC3 (rat): Y380‑p
Characterization
Methods used to characterize site in vivo [32P] bio-synthetic labeling, mutation of modification site, phospho-antibody, phosphopeptide mapping
Disease tissue studied:  adrenal cancer, pheochromocytoma
Relevant cell lines - cell types - tissues:  COS (fibroblast), PC-12 (chromaffin)
Cellular systems studied:  cell lines
Species studied:  green monkey, rat
Enzymes shown to modify site in vitro
Type Enzyme
KINASE TrkA (human)
KINASE TrkB (human)
KINASE EGFR (human)
KINASE Src (human)
KINASE EGFR (human)
KINASE TrkA (human)
KINASE Src (human)
KINASE TrkB (human)
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
NGF increase
EGF increase

Y283-p - SHC3 iso2 (human)
Modsite: RQGSSDIySTPEGKL SwissProt Entrez-Gene
Orthologous residues
SHC3 (human): Y406‑p, SHC3 iso2 (human): Y283‑p, SHC3 (mouse): Y286‑p, SHC3 (rat): Y406‑p
Characterization
Methods used to characterize site in vivo [32P] bio-synthetic labeling, mutation of modification site, phospho-antibody, phosphopeptide mapping
Disease tissue studied:  adrenal cancer, pheochromocytoma
Relevant cell lines - cell types - tissues:  COS (fibroblast), PC-12 (chromaffin)
Cellular systems studied:  cell lines
Species studied:  green monkey, rat
Enzymes shown to modify site in vitro
Type Enzyme
KINASE Src (human)
KINASE EGFR (human)
KINASE TrkA (human)
KINASE TrkB (human)
KINASE EGFR (human)
KINASE TrkA (human)
KINASE Src (human)
KINASE TrkB (human)
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
NGF increase
EGF increase
Downstream Regulation
Effect of modification (function):  molecular association, regulation
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
RAPGEF1 (human) Induces pull-down assay
CRK (human) Induces pull-down assay

Y301-p - SHC3 iso2 (human)
Modsite: PTGEAPTyVNTQQIP SwissProt Entrez-Gene
Orthologous residues
SHC3 (human): Y424‑p, SHC3 iso2 (human): Y301‑p, SHC3 (mouse): Y304‑p, SHC3 (rat): Y424‑p
Characterization
Methods used to characterize site in vivo [32P] bio-synthetic labeling, mutation of modification site, phospho-antibody, phosphopeptide mapping
Disease tissue studied:  adrenal cancer, pheochromocytoma
Relevant cell lines - cell types - tissues:  COS (fibroblast), PC-12 (chromaffin)
Cellular systems studied:  cell lines
Species studied:  green monkey, rat
Enzymes shown to modify site in vitro
Type Enzyme
KINASE TrkB (human)
KINASE EGFR (human)
KINASE Src (human)
KINASE TrkA (human)
KINASE EGFR (human)
KINASE EGFR (human)
KINASE TrkB (human)
KINASE TrkA (human)
KINASE TrkB (human)
KINASE TrkA (human)
KINASE Src (human)
KINASE Src (human)
Downstream Regulation
Effect of modification (function):  activity, induced, molecular association, regulation, phosphorylation
Effect of modification (process):  transcription, altered
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
DYN1 (human) Induces pull-down assay
GRB2 (human) Induces pull-down assay
SOS1 (human) Induces pull-down assay
Comments:  ERK activation